NasdaqGM - Nasdaq Real Time Price USD

Theravance Biopharma, Inc. (TBPH)

Compare

8.62

+0.02

+(0.29%)

At close: April 17 at 4:00:00 PM EDT

8.62

0.00

(0.00%)

After hours: April 17 at 4:02:19 PM EDT

Theravance Biopharma Presents Two New Ampreloxetine Analyses in Oral Session at the American Academy of Neurology 2025 Annual Meeting

Theravance Biopharma, Inc. ("Theravance Biopharma" or the "Company") (NASDAQ: TBPH) today announced new analyses from its previous Phase 3 program evaluating ampreloxetine, an investigational medicine for the treatment of symptomatic neurogenic orthostatic hypotension (nOH). Both analyses were presented as platform presentations at the 77th Annual Meeting of the American Academy of Neurology (AAN) Meeting, taking place April 5-9, 2025, in San Diego, California. Findings support ampreloxetine's h

PR Newswire 11 days ago

TBPH
+0.29%
Theravance Biopharma to Participate in an Upcoming Investor Conference

Theravance Biopharma, Inc. (NASDAQ: TBPH) will participate in a fireside chat at the Jones Healthcare and Technology Innovation Conference in Las Vegas on Wednesday, April 9 at 11:30 am PDT (2:30 pm EDT/6:30 PM GMT).

PR Newswire 18 days ago

TBPH
+0.29%
Why Is Theravance Bio (TBPH) Up 0.4% Since Last Earnings Report?

Theravance Bio (TBPH) reported earnings 30 days ago. What's next for the stock? We take a look at earnings estimates for some clues.

Zacks 21 days ago

TBPH
+0.29%
^GSPC
Theravance Biopharma to Present New Ampreloxetine Analyses in Neurogenic Orthostatic Hypotension (nOH) at the 77th Annual Meeting of the American Academy of Neurology

Theravance Biopharma, Inc. ("Theravance Biopharma" or the "Company") (NASDAQ: TBPH) today announced new analyses of the initial Phase 3 program of ampreloxetine (Studies 169 and 170) supporting its selective and differentiated pharmacodynamic profile will be presented at the 77th Annual Meeting of the American Academy of Neurology (AAN) Meeting, taking place April 5-9, 2025, in San Diego, California. Results from these initial studies led to the initiation of a Phase 3 confirmatory study (CYPRES

PR Newswire 22 days ago

TBPH
+0.29%
Theravance Biopharma Full Year 2024 Earnings: Revenues Beat Expectations, EPS Lags

Theravance Biopharma ( NASDAQ:TBPH ) Full Year 2024 Results Key Financial Results Revenue: US$64.4m (up 12% from FY...

Simply Wall St. last month

TBPH
+0.29%
Theravance's Q4 Loss In Line With Estimates, Sales Beat

TBPH's fourth-quarter earnings match estimates while sales beat the same marginally. Increased collaboration revenues from Viatris drive revenues higher.

Zacks last month

TBPH
+0.29%
VTRS
Theravance Biopharma Inc (TBPH) Q4 2024 Earnings Call Highlights: Record Sales and Strategic ...

Theravance Biopharma Inc (TBPH) reports robust growth in Upell sales and secures a significant milestone payment, while navigating regulatory and market challenges.

GuruFocus.com last month

TBPH
+0.29%
Theravance Biopharma (TBPH) Reports Q4 Loss, Tops Revenue Estimates

Theravance Bio (TBPH) delivered earnings and revenue surprises of 0% and 3.50%, respectively, for the quarter ended December 2024. Do the numbers hold clues to what lies ahead for the stock?

Zacks last month

TBPH
+0.29%
PSTV
Theravance Biopharma, Inc. Reports Record Fourth Quarter and Full Year 2024 Financial Results

Theravance Biopharma, Inc. ("Theravance Biopharma" or the "Company") (NASDAQ: TBPH) today announced financial and operational results for the fourth quarter and full-year ended December 31, 2024.

PR Newswire last month

TBPH
+0.29%
Here's Why We're Not At All Concerned With Theravance Biopharma's (NASDAQ:TBPH) Cash Burn Situation

There's no doubt that money can be made by owning shares of unprofitable businesses. For example, although Amazon.com...

Simply Wall St. 2 months ago

TBPH
+0.29%
Theravance Biopharma to Report Fourth Quarter and Full Year 2024 Financial Results on February 26, 2025

Theravance Biopharma, Inc. (NASDAQ: TBPH) will report its fourth quarter and full year 2024 financial results and provide a business update after market close on Wednesday, February 26, 2025. An accompanying conference call and simultaneous webcast will be hosted at 5:00 pm EST (2:00 pm PST/10:00 pm GMT) that day.

PR Newswire 2 months ago

TBPH
+0.29%
Theravance Bio (TBPH) Soars 8.3%: Is Further Upside Left in the Stock?

Theravance Bio (TBPH) saw its shares surge in the last session with trading volume being higher than average. The latest trend in earnings estimate revisions may not translate into further price increase in the near term.

Zacks 2 months ago

TBPH
+0.29%
ECOR
Ozempic, Xtandi among next 15 drugs selected for U.S. price talks

The Department of Health and Human Services, through the Centers for Medicare & Medicaid Services, announced the selection of 15 additional drugs covered under Medicare Part D for price negotiations. In accordance with the Inflation Reduction Act, the negotiations with participating drug companies for these 15 drugs will occur in 2025 and any negotiated prices will become effective in 2027, the agency said in a statement. The selected drug list for the second cycle of negotiations is: Novo Nordi

TipRanks 2 months ago

NONOF

NVO

BMY
Analysts Are Optimistic We'll See A Profit From Theravance Biopharma, Inc. (NASDAQ:TBPH)

With the business potentially at an important milestone, we thought we'd take a closer look at Theravance Biopharma...

Simply Wall St. 3 months ago

TBPH
+0.29%
Theravance Biopharma to Conduct Investor Meetings During the J.P. Morgan 43rd Annual Healthcare Conference

Theravance Biopharma, Inc. ("Theravance Biopharma" or the "Company") (NASDAQ: TBPH) today announced that members of its management team will hold investor meetings during the 43rd Annual J.P. Morgan Healthcare Conference, January 13-16, 2025, in San Francisco, CA.

PR Newswire 3 months ago

TBPH
+0.29%
Theravance Bio (TBPH) Up 3.7% Since Last Earnings Report: Can It Continue?

Theravance Bio (TBPH) reported earnings 30 days ago. What's next for the stock? We take a look at earnings estimates for some clues.

Zacks 4 months ago

TBPH
+0.29%
IONS
The past five years for Theravance Biopharma (NASDAQ:TBPH) investors has not been profitable

While it may not be enough for some shareholders, we think it is good to see the Theravance Biopharma, Inc...

Simply Wall St. 4 months ago

TBPH
+0.29%
Theravance Biopharma Third Quarter 2024 Earnings: Revenues Beat Expectations, EPS Lags

Theravance Biopharma ( NASDAQ:TBPH ) Third Quarter 2024 Results Key Financial Results Revenue: US$16.9m (up 7.5% from...

Simply Wall St. 5 months ago

TBPH
+0.29%
Theravance's Q3 Loss Narrower Than Expected, Revenues Rise Y/Y

TBPH beats third-quarter estimates for both sales and earnings. Increased collaboration revenues from Viatris drive year-over-year top-line performance.

Zacks 5 months ago

TBPH
+0.29%
VTRS
Theravance Biopharma Inc (TBPH) Q3 2024 Earnings Call Highlights: Strong Sales Growth and ...

Theravance Biopharma Inc (TBPH) reports robust quarterly sales growth and outlines strategic plans to enhance shareholder value amidst market challenges.

GuruFocus.com 5 months ago

TBPH
+0.29%

Performance Overview

Return	TBPH	S&P 500 (^GSPC)
YTD	-8.40%	-10.18%
1-Year	-9.45%	+5.19%
3-Year	-13.19%	+20.26%

News

Life

Entertainment

Finance

Sports

New on Yahoo

Yahoo Finance

Theravance Biopharma, Inc. (TBPH)

Theravance Biopharma Presents Two New Ampreloxetine Analyses in Oral Session at the American Academy of Neurology 2025 Annual Meeting

Theravance Biopharma to Participate in an Upcoming Investor Conference

Why Is Theravance Bio (TBPH) Up 0.4% Since Last Earnings Report?

Theravance Biopharma to Present New Ampreloxetine Analyses in Neurogenic Orthostatic Hypotension (nOH) at the 77th Annual Meeting of the American Academy of Neurology

Theravance Biopharma Full Year 2024 Earnings: Revenues Beat Expectations, EPS Lags

Theravance's Q4 Loss In Line With Estimates, Sales Beat

Theravance Biopharma Inc (TBPH) Q4 2024 Earnings Call Highlights: Record Sales and Strategic ...

Theravance Biopharma (TBPH) Reports Q4 Loss, Tops Revenue Estimates

Theravance Biopharma, Inc. Reports Record Fourth Quarter and Full Year 2024 Financial Results

Here's Why We're Not At All Concerned With Theravance Biopharma's (NASDAQ:TBPH) Cash Burn Situation

Theravance Biopharma to Report Fourth Quarter and Full Year 2024 Financial Results on February 26, 2025

Theravance Bio (TBPH) Soars 8.3%: Is Further Upside Left in the Stock?

Ozempic, Xtandi among next 15 drugs selected for U.S. price talks

Analysts Are Optimistic We'll See A Profit From Theravance Biopharma, Inc. (NASDAQ:TBPH)

Theravance Biopharma to Conduct Investor Meetings During the J.P. Morgan 43rd Annual Healthcare Conference

Theravance Bio (TBPH) Up 3.7% Since Last Earnings Report: Can It Continue?

The past five years for Theravance Biopharma (NASDAQ:TBPH) investors has not been profitable

Theravance Biopharma Third Quarter 2024 Earnings: Revenues Beat Expectations, EPS Lags

Theravance's Q3 Loss Narrower Than Expected, Revenues Rise Y/Y

Theravance Biopharma Inc (TBPH) Q3 2024 Earnings Call Highlights: Strong Sales Growth and ...

Performance Overview